Minodronate Osteoporosis

Minodronate Osteoporosis drug from Japan For some time researchers have known that this drug increased bone density but there was a lack of research as to whether or not it really reduced the risk of fractures. Japanese researchers havefound that daily does of this bisphosophante reduces spinal fractures. What follows is taken from the abstract of their report found in Osteoporosis International in August2009.

Abstract:

"Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study" by T. Matsumoto,corresponding author H. Hagino, M. Shiraki, M. Fukunaga, T. Nakano, K. Takaoka,6 H. Morii, Y. Ohashi, and T. Nakamura.

Summary: A randomized placebo-controlled trial was conducted to examine the effect of daily oral 1 mg minodronate on vertebral fractures in 704 postmenopausal women with established osteoporosis for 24 months. Minodronate treatment reduced vertebral fractures by 59% without serious adverse events. Minodronate is a safe and effective bisphosphonate for osteoporosis treatment.

Introduction Minodronate increases bone mineral density (BMD) in postmenopausal osteoporotic patients. However, its efficacy in reducing osteoporotic fractures has not been tested.

MethodsTo examine anti-fracture efficacy and safety of daily oral minodronate in postmenopausal women with established osteoporosis, a randomized, double-blind, placebo-controlled trial was conducted in 704 postmenopausal women (55 to 80 years) with one to five vertebral fractures and low BMD. Subjects were randomly assigned to receive daily oral 1 mg minodronate (n = 359) or placebo (n = 345) for 24 months, with daily supplements of 600 mg calcium and 200 IU vitamin D3.

Results of this Minodronate Osteoporosis studyDaily 1 mg minodronate for 24 months reduced the risk of vertebral fractures by 59% (95% CI, 36.6–73.3%). Furthermore, when fractures during the first 6 months were eliminated, the risk of vertebral fractures from 6 to 24 months was reduced by 74% in minodronate-treated group. Minodronate treatment also reduced height loss. Bone turnover markers were suppressed by about 50% after 6 months of minodronate treatment and remained suppressed thereafter. The overall safety profile including gastrointestinal safety was similar between the two groups.

Conclusions: Daily oral minodronate is safe, well-tolerated, and is effective in reducing vertebral fracture risk in postmenopausal women with established osteoporosis.

Other effects of Minodronate Osteoporosis drug

It appears that Minodronate Osteoporosis drug may have some anti-cancer properties.

• Melanoma Minodronate, a Newly Developed Nitrogen-Containing Bisphosphonate, Suppresses Melanoma Growth and Improves Survival in Nude Mice by Blocking Vascular Endothelial Growth Factor Signaling. Sho-ichi Yamagishi, Riichiro Abe, Yosuke Inagaki, Kazuo Nakamura, Hiroshi Sugawara, Daisuke Inokuma, Hideki Nakamura, Tadamichi Shimizu, Masayoshi Takeuchi, Akihiko Yoshimura, Richard Bucala, Hiroshi Shimizu, and Tsutomu Imaizumi. Am J Pathol. 2004 December; 165(6): 1865–1874.
• Bladder cancerA third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo K Sato, T Yuasa, M Nogawa, S Kimura, H Segawa, A Yokota, and T Maekawa. Br J Cancer. 2006 November 20; 95(10): 1354–1361.
• Anti-tumor effect of bisphosphonate (YM529) on non-small cell lung cancer cell linesRyuichiro Koshimune, Motoi Aoe, Shinichi Toyooka, Fumikata Hara, Mamoru Ouchida, Masaki Tokumo, Yoshifumi Sano, Hiroshi Date, and Nobuyoshi ShimizuBMC Cancer. 2007; 7: 8. Note: YM529 is Mindoronate Osteoporosis drug.

End of information about Minodronate Osteoporosis drug.

Click here for: Medications in addition to Minodronate Osteoporosis drug

HOME